Moderna reports on an update to the agreement with Israel's Ministry of Health for the supply of additional mRNA vaccines
Moderna provides updates on the clinical development and production of the Mrna-1273 vaccine for COVID-19 it has developed.
- in a letter The New England Journal of Medicine (NEJM) has published interim data from the National Institutes of Health (NIH)-led phase 1 clinical study on mRNA-1273.
- According to the data, on day 119 (3 months after giving a second dose of 100 μg), the levels of binding and neutralizing antibodies remained high among all participants; with consistent results in all age groups (18-55, 56-70 and 71 and over).
- Moderna expects the availability of 100 to 125 million vaccine doses worldwide in the first quarter of 2021 (85-100 million of the aforementioned vaccine doses will be available in the US and 15 to 25 million vaccine doses will be available outside the US).
- The scope of the vaccine doses for the first quarter are included in the company's expectations for the production of 500 million to 1 billion vaccine doses worldwide in 2021.
"Interim data from a phase 1 clinical trial indicate that mRNA-1273, our vaccine for the treatment of COVID-19, can produce neutralizing and resistant antibodies in all age groups including adults and the elderly. […] These data instill in us additional hope and it is expected that the high level of efficiency achieved with the mRNA-1273 vaccine for the prevention of the COVID-19 disease will be maintained.” Dr. Tal Zaks, Medical Director of Moderna, said.
An improved agreement to bring vaccines to Israel
Moderna (NASDAQ: MRNA) today announces the expansion of the agreement with the Israeli Ministry of Health to supply 4 million additional doses of mRNA-1273, Moderna's vaccine for the treatment of COVID-19. The Israeli government thereby guarantees the supply of 6 million doses of mRNA-1273. This agreement will support the ongoing efforts of the Ministry of Health to ensure early availability of the vaccine against COVID-19 for the residents of Israel. The company has begun the regulatory approval process with the Ministry of Health in Israel.
These vaccines will make it possible to vaccinate three million Israelis because two doses of it are required to obtain a vaccine.
"We appreciate the confidence on the part of the Israeli government and the Ministry of Health in mRNA-1273, our vaccine against COVID-19, as reflected in this second order," said Stephan Bansel, CEO of Moderna. "We are proud of the progress we have achieved so far with mRNA-1273, including the positive initial results for vaccine efficacy as recently reported in the phase 3 trial, COVE Study. We will maintain continuous contact with Israel's Ministry of Health as we continue to progress in the development of our vaccine."
"The experiments showed that the experiment is safe and effective"
On November 30, Moderna reported that the main efficacy findings in the phase 3 trial of mRNA-1273 as obtained from an analysis of 196 cases confirmed the high efficacy shown in the initial interim results. The results of the experiment indicate a vaccine effectiveness of 94.1%.
Safety data have been maintained and the study continues to be conducted under the review of an independent monitoring safety review board (DSMB) of the National Institutes of Health (NIH). Based on analysis of previous results, the most common side effects observed included pain at the injection site, fatigue, muscle pain, arthralgia, headache, and pain/redness at the injection site. According to the data, in the mRNA-1273 group in the study, an increase in the frequency and severity of side effects was observed after the second administration of the vaccine. The phase 3 clinical trial, known as the COVE study, included over 30,000 participants in the US and was conducted in collaboration with NIAID, which is part of the NIH and the Biological Advanced Research and Development Authority (BARDA), in the Preparedness and Response Department of the United States Department of Health.
Moderna continues to increase its global production volume to be ready to supply approximately 500 million vaccine doses per year, and possibly up to one billion doses per year, starting in 2021. The company is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, to manufacture the vaccine doses outside to the USA. This is a dedicated supply chain to support countries outside the United States that have entered into purchasing agreements with Moderna.
More of the topic in Hayadan:
- Moderna's COVID-19 vaccine achieved 94.5% efficacy in the clinical trial
- Highly effective coronavirus antibodies identified will form the basis of a passive COVID-19 vaccine
- Hebrew University researchers in a recent analysis of the Corona data: "There is still a long time before it will be necessary to talk about a full closure" (3 / 12 / 2020)
4 תגובות
Need more guinea pigs. It is already better to wear a mask and keep a distance than to inject a vaccine that was developed at a suspicious speed and that is based on a technology that humanity has not yet known.
Why don't they inform the public about the booster of immune response in every injection, now and in every vaccine
was in the past. What is the material and what is the quantity. Obviously there are people who react to all kinds of degrees to everything
Medicine and there is no truth in "sedation" as if only a local reaction. It is clear that fever etc. are a result
of Adgement and not of the ear of the virus. And there is a reasonable suspicion that an epidemic of allergies and autoimmune diseases, including a brain attack and a pancreatic attack, is the result of Adagement, which they overdid.
By the way - until 1985 the public was not given information about food colorings and I suffered from migraines for years
And I took the best pills...maybe selling pills was a hidden goal of hiding an informant?
Because all the suffering caused to me was because of yellow dye - tetrazine. No other colors and no food additives.
What about those who have already contracted the corona virus, can they get vaccinated and that can help?
Hello you guys
I am looking for information about the vaccines:
How long and if at all, can I get infected after the first dose?
And the same after the second dose, and of course will the vaccine work if I was vaccinated with the first dose after I had not yet discovered that I was infected, etc.
Thank you